cjc 1295 dac vs ipamorelin CJC-1295 + CJC-1295 Without DAC / Ipamorelin

Serum IGF-1 levels remained unchanged, confirming the peptide does not activate growth-promoting pathways

Its medical use is experimental or off-label

It is commonly paired with Ipamorelin, a synthetic peptide studied in laboratory models for its selective interaction with growth hormonerelated signaling pathways

Synergistic Amplification Mechanism When combined, CJC-1295 (NO DAC) and ipamorelin blend peptide create a complementary effect through activation of distinct receptor families: CJC-1295 amplifies the frequency and baseline of growth hormone pulses via GHRH receptor stimulation Ipamorelin increases the amplitude (peak height) of growth hormone pulses via ghrelin receptor activation Combined administration results in 3- to 5-fold greater growth hormone release compared to either peptide alone Maintenance of natural pulsatile secretion pattern prevents receptor desensitization The mechanism involves cooperative signaling through the cyclic AMP (cAMP) and phospholipase C pathways, with GHRH receptor activation increasing intracellular cAMP levels while ghrelin receptor activation potentiates calcium mobilization in somatotroph cells

Ipamorelin and Sermorelin are both peptides that belong to a class of compounds known as growth hormone-releasing peptides (GHRPs)